MBA BSCPT - Cardiol Therapeutics Vice Development

CRDL Stock  CAD 2.03  0.01  0.49%   

Executive

MBA BSCPT is Vice Development of Cardiol Therapeutics Class
Address 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Phone289-910-0850
Webhttps://www.cardiolrx.com

Cardiol Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.5415) % which means that it has lost $0.5415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0844) %, meaning that it generated substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Tangible Assets is likely to drop to -0.81. In addition to that, Return On Capital Employed is likely to drop to -1.1. At this time, Cardiol Therapeutics' Total Assets are very stable compared to the past year. As of the 11th of December 2024, Non Current Assets Total is likely to grow to about 610.6 K, while Net Tangible Assets are likely to drop about 32.7 M.
Cardiol Therapeutics Class has accumulated 174.34 K in total debt with debt to equity ratio (D/E) of 1.0, which is about average as compared to similar companies. Cardiol Therapeutics has a current ratio of 24.18, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cardiol Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cardiol Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cardiol Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cardiol to invest in growth at high rates of return. When we think about Cardiol Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Marcel BonnMillerCharlottes Web Holdings
N/A
Jessica SaxtonCharlottes Web Holdings
36
MD FCAPMedicenna Therapeutics Corp
N/A
Karolina UrbanAvicanna
N/A
Erika LindCharlottes Web Holdings
N/A
Kelly SheaCharlottes Web Holdings
N/A
Stephen KimAvicanna
N/A
Enric PujolAvicanna
N/A
Raymond KunkelCharlottes Web Holdings
58
Tim OrrCharlottes Web Holdings
N/A
Greg GouldCharlottes Web Holdings
N/A
Sarah CambridgeCharlottes Web Holdings
36
Frantz DevedecAvicanna
N/A
Ivana MaricAvicanna
N/A
Andrew ShaferCharlottes Web Holdings
N/A
Arash MBAAvicanna
N/A
CBV CAMedicenna Therapeutics Corp
51
Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company was incorporated in 2017 and is headquartered in Oakville, Canada. CARDIOL THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 6 people. Cardiol Therapeutics Class (CRDL) is traded on Toronto Exchange in Canada and employs 7 people. Cardiol Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Cardiol Therapeutics Leadership Team

Elected by the shareholders, the Cardiol Therapeutics' board of directors comprises two types of representatives: Cardiol Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardiol. The board's role is to monitor Cardiol Therapeutics' management team and ensure that shareholders' interests are well served. Cardiol Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardiol Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew MD, Chief Development
Trevor Burns, Investor Relations
Bernard BSc, Chief Officer
MBA BSCPT, Vice Development
MBA MBA, CEO Pres
David MBA, CEO President
CA CMA, Corp CFO

Cardiol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardiol Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Cardiol Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cardiol Stock

  0.84AEMC Alaska Energy MetalsPairCorr
  0.76CMC Cielo Waste Solutions Earnings Call This WeekPairCorr

Moving against Cardiol Stock

  0.81MATE Blockmate VenturesPairCorr
  0.74LQWD LQwD FinTech CorpPairCorr
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.